Trial Profile

A Phase 2, Open-label, Randomized, Two-part, Multiple Dose Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic Hepatitis B Virus

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Inarigivir soproxil (Primary) ; Tenofovir disoproxil fumarate
Indications Hepatitis B
Focus Adverse reactions; Therapeutic Use
Acronyms ACHIEVE
Sponsors F-star Therapeutics; Spring Bank Pharmaceuticals

Most Recent Events

01 Jan 2023 Results published in the Liver International
17 Oct 2019 Status changed from active, no longer recruiting to completed, according to a Spring Bank Pharmaceuticals media release.
29 Apr 2019 According to a Spring Bank Pharmaceuticals media release, the company expects to announce initial results from an exploratory cohort of NUC-suppressed chronic HBV patients at a major scientific conference in the second half of 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com